Repligen (RGEN) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Repligen Corp  (NASDAQ: RGEN)


Repligen's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Repligen's ROA in the second quarter of 2026?
Repligen Corp achieved a return on average assets (ROA) of 1.41 % in its second quarter of 2026, which is below Repligen's average return on assets, which stands at 5.2%.

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 196 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 1891, from total ROA ranking in the first quarter of 2026 at 2249.

What is ROA?



Return On Assets (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 1.67 % 2.76 % 9.38 % 8.06 % 6.01 %
Y / Y Net Income Change -66.31 % 42.93 % - - 160.21 %
Net Income (TTM) in million 42 51 49 2 -14
Return On Assets (TTM) 1.41 % 1.76 % 1.68 % 0.06 % -0.5 %
RGEN's Total Ranking # 1891 # 2249 # 2546 # 2658 # 2722
Total Assets (TTM) in million 2,950 2,931 2,950 2,924 2,902
Seq. Total Assets Change 0.66 % -0.64 % 0.89 % 0.76 % 1.73 %
Seq. Net Income Change -39.9 % -37.28 % -10.89 % 0.3 % 154.99 %



Return On Assets Company Ranking
Within: No.
Industry # 22
Sector # 197
Overall # 1984

Return On Assets Statistics
High Average Low
20.18 %
5.2 %
-0.9 %
(Sep 30 2013)   (Dec 31 2024)





Financial Statements
Repligen's Assets $ 2,950 million RGEN's Balance sheet
Repligen's Income $ 5 million Quarterly RGEN's Income Statement
RGEN's Income by Division See RGEN's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025
(Dec 31 2024)
FY 2024
(Dec 31 2023)
FY 2023
(Dec 31 2022)
FY 2022
(Dec 31 2021)
FY 2021
Y / Y Total Assets Change 9.38 % -0.78 % 13.2 % 6.27 % 20.23 %
Total Assets in million 2,950 2,697 2,718 2,401 2,259
Y / Y Net Income Change - - -80.86 % 44.95 % 114.08 %
Net Income in million 49 -26 36 186 128
Annual Return On Assets 1.66 % -0.95 % 1.31 % 7.75 % 5.68 %




Comment on RGEN's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 1.66 % compared to prior year, due to annual net income growth of % to $48.89 million, while value of Repligen's overall assets grew just by 9.38 % to $2,949.70 million, compared to $2,949.70 a year before.


More Return On Assets Ratios
RGEN's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RGEN's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RGEN's Competitors
Subscribers only: Roa for Repligen's Suppliers
Subscribers only: Return On Assets for RGEN's Customers

You may also want to know
RGEN's Roi RGEN's Inventory Turnover Ratio RGEN's Growth Rates RGEN's Dividend Comparisons
RGEN's Profitability Ratios RGEN's Asset Turnover Ratio RGEN's Dividend Growth
RGEN's Roe RGEN's Valuation Ratios RGEN's Financial Strength Ratios RGEN's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Henry Schein Inc   3.79 %
Integer Holdings Corporation  3.76 %
Zimmer Biomet Holdings Inc   3.51 %
Ardent Health Inc   3.22 %
Community Health Systems Inc   3.17 %
Vaso Corporation  2.92 %
Collegium Pharmaceutical Inc   2.72 %
National Vision Holdings Inc   2.53 %
Conmed Corporation  2.44 %
Merck and Co Inc   2.42 %
Privia Health Group Inc   2.41 %
Lifestance Health Group Inc   2.33 %
Bio rad Laboratories Inc   2.21 %
Pfizer Inc  2.12 %
Mimedx Group Inc   1.99 %
Revvity Inc  1.97 %
Alkermes Plc   1.96 %
Becton Dickinson And Company  1.77 %
Teva Pharmaceutical Industries Limited  1.77 %
Immucell Corporation  1.76 %
Envista Holdings Corporation  1.69 %
Atricure Inc   1.62 %
Black Hawk Acquisition Corporation  1.56 %
Repligen Corp  1.41 %
Omada Health Inc   1.41 %
Arvinas Inc   1.29 %
Pacira Biosciences inc   1.17 %
Waters Corporation  1.12 %
Cormedix Inc   1.11 %
Warby Parker Inc   1.05 %


Date modified: 2026-09-26T07:09:41+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.